Posted by Michael Wonder on 08 Jul 2019
Prevail Therapeutics receives U.S. FDA fast track designation for PR001 for the treatment of Parkinson’s disease patients with a GBA1 mutation
8 July 2019 - Company plans to initiate Phase 1/2 clinical trial in the second half of 2019.
Prevail Therapeutics today announced that the U.S. FDA has granted fast track designation for the Company’s lead gene therapy program, PR001, for the treatment of Parkinson’s disease patients with a GBA1 mutation (PD-GBA).
PR001 is a potentially disease-modifying, single-dose, AAV9-based gene therapy being developed for the treatment of PD-GBA and neuronopathic Gaucher disease.
